MODERATOR
:
SPEAKER
(S):
Susan Johnson, MSTM, MT(ASCP)SBB, Director, Clinical Education, BloodCenter of Wisconsin
Drug-induced autoimmune hemolytic anemia,,
Patricia Arndt, MS, MT(ASCP)SBB, Senior Research Associate, American Red Cross
Investigation of a negative DAT in the setting of clinical hemolysis
Katrina Billingsley, MT(ASCP)SBB, Supervisor, Clinical Immunogenetics, LifeShare Blood Centers
The role of red cell genotyping for patients having a positive DAT
Description
This workshop, which is part of the complex serological investigation (CSI) series, will focus on the direct antiglobulin test (DAT) and hemolytic anemia. Using case studies, the faculty will demonstrate how a positive DAT can be due to drugs, autoimmune disease or a delayed transfusion reaction. Special techniques will be presented including the role of red cell blood group genotyping to provide blood for these patients.
-
Demonstrate how red cell genotyping can be used to differentiate between WAIHA and a delayed transfusion reaction.
-
List tests that can be performed to investigate negative DATs in the setting of clinical hemolysis.
-
Outline a protocol for the serologic investigation of a drug-induced hemolytic anemia.
CE Category | CE Value |
---|
California Clinical Laboratory Personnel |
1.5 |
California Nurse |
1.8 |
Florida Laboratory Personnel |
1.8 |
General Attendee |
1.5 |
Physician |
1.5 |
Please note: Continuing education (CE) credit is available for online offerings only. Individuals that purchase CD-ROMs will not receive CE credit for the programs they view.